Valvular & structural heart disease

Aortic valve neocuspidization using the Ozaki technique: A meta-analysis of reconstructed patient-level data

Am Heart JPublished Systematic review and meta-analysis of reconstructed patient-level data

Authors' conclusion

The midterm outcomes of the Ozaki procedure are excellent in terms of hemodynamics, survival, and freedom from reoperation.

Study context

Population
Adults and children undergoing aortic valve neocuspidization (Ozaki reconstruction)
Participants
1,891 adults22 studies
Outcome
Freedom from reoperation (reconstructed patient-level data)
Follow-up
1, 3 and 5 years
Methodological detailssingle-arm, PubMed and Cochrane searched up to November 13, 2021; individual patient data reconstructed from Kaplan-Meier curves
  • Single-arm
  • PubMed and Cochrane searched up to November 13, 2021; individual patient data reconstructed from Kaplan-Meier curves

Pooled result

As reported in the abstract

In-hospital mortality

0.7%

95% CI 0.1–1.7

Late mortality (mean follow-up 38.1 ± 23.8 months)

1.9%

Further pooled results

Procedural characteristics

Mean age at surgery (± SD), years
43.2 ± 24.5
Mean age, adults
65 ± 12.3 years
Mean age, pediatric
12.3 ± 3.8 years
Indication AS
46.4%, 95% CI 34.1-58.6
Mean cross-clamp time
106.8 ± 24.8 minutes
Mean cardiopulmonary bypass time
135.2 ± 35.1 minutes

Reoperations due to infective endocarditis

Share of reoperations due to infective endocarditis
51.5%, 95% CI 18.3-84.0

Safety

Permanent pacemaker implantation

Permanent pacemaker
0.7% (95% CI 0.4-1.2)

Endocarditis

Risk of endocarditis per patient per year
0.5%

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Aortic valve neocuspidization using the Ozaki technique: A meta-analysis of reconstructed patient-level data. Am Heart J. Published 14 September 2022. doi:10.1016/j.ahj.2022.09.003

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.